姜兴武 - 复旦大学 - 材料科学系

个人简介

教育和工作经历 2021/02-至今，复旦大学，材料科学系，青年副研究员 2019/03-2021/01，同济大学，医学院，博士后 2013/09-2019/01，华东师范大学，生命科学学院，博士学位 2009/09-2013/06，西北农林科技大学，动物科技学院，学士学位

研究领域

新型无机非金属材料的合成及其抗肿瘤应用研究新型功能材料用于肝脏代谢类疾病研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Yang Liu, Shaojie Zhai, Xingwu Jiang*, Yanyan Liu, Kun Wang, Chaochao Wang, Meng Zhang, Xuanyong Liu*, Wenbo Bu*. Intracellular mutual promotion of redox homeostasis regulation and iron metabolism disruption for enduring chemodynamic therapy. [J]. Advanced Functional Materials, 2021, 2010390. Yifei Yin#, Xingwu Jiang#, Liping Sun#, Hongyan Li, Chunxia Su, Yan Zhang, Guang Xu, Xiaolong Li, Chongke Zhao, Yu Chen*, Huixiong Xu*, Kun Zhang*. Continuous inertial cavitation evokes massive ROS for reinforcing sonodynamic therapy and immunogenic cell death against breast carcinoma[J]. Nano Today, 2021, 36: 101009. BeiEr Jiang#, Xingwu Jiang#, Qiansen Zhang, Qiuwen Liang, Zi-Liang Qiu, Xiang-Bai Sun, Jun-Jie Yang, Si Chen, Chunyang Yi, Xiaolei Chai, Mingyao Liu, Li-Fang Yu*, Weiqiang Lu*, Han-Kun Zhang*.From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis[J]. Journal of Medicinal Chemistry, 2021 Jan 14;64(1):385-403. Xingwu Jiang#, Si Chen#, Qiansen Zhang, Chunyang Yi, Jiacheng He, Xiyun Ye, Mingyao Liu, Weiqiang Lu*. Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis[J]. Phytomedicine.2020, Feb;67:153160. XingWu Jiang#, BeiEr Jiang#, Hao Liu, ZhiTao Liu, LongLong Hu, Mingyao Liu, Weiqiang Lu, HanKun Zhang, Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists [J].European Journal of Medicinal Chemistry, 2018 Oct 5;158:123-133. Xingwu Jiang#, Weiqiang Lu#, Xiaoyang Shen#, Quan Wang, Jing Lv, Mingyao Liu, Feixiong Cheng*, Zhongming Zhao*, Xiufeng Pang*. Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy [J]. JCI insight, 2018, 3(11).